What is the Chinese (CN) name for Ozempix? The provided information doesnt include any details about a product named… https://www.Drugchatter.com/chat/36985/ozempix-chinese-name/

Which Chinese pharmaceutical companies are investing in AI? A number of Chinese drugmakers have been putting money into… https://www.Drugchatter.com/chat/50765/chinese-pharmsutical-company-investing-in-ai/

Is Gleevec (imatinib) among the most expensive drugs? Gleevec (imatinib) is widely known as an expensive cancer medicine,… https://www.Drugchatter.com/chat/31710/is-gleevec-the-most-expensive-drug/

Branded Generics vs. Commodity Generics: How Brand Trust Wins Market Share
In generic drugs, the conversation is often framed as a race to the bottom: lowest price, fastest approvals, highest volume. But in the real worldwhere formularies tighten, phar…

Pharma has a timing problemand its getting more expensive.
In a world where launches are measured in weeks, not quarters, the patent first mindset is quickly shifting from legal strategy to commercial advantage. The core idea is simple: align IP filing…

Dont Get Blindsided: The Critical Drug Patent Mistakes That Can Sink M&A Due Diligence in Massachusetts
In life sciences M&A, the deal can look perfect on paperuntil a single patent detail turns a strategic acquisition into a costly scramble.
M…

Post-approval patents are supposed to be the aftercare of innovationextensions, tweaks, and new claims that keep therapies protected as they move from launch into real-world use. But for brand teams, generics counsel, and investors, theres a quieter st…

Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…

Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity
The public conversation about drug exclusivity often starts and ends with a single number: 20 years. Its a clean headline. Its also a misleading shortcut.
In reality, the lengthand ev…

Pharma mega-deals dont start with spreadsheets. They start with exclusivity.
If youve ever wondered why two companies can look at the same asset and arrive at wildly different valuations, the answer is often hiding in plain sight: the patchwork of lega…